[ad_1]
On March 3, 2023,
Dawson James
initiated coverage of Geovax Labs with
a Buy recommendation.
Analyst Price Forecast Suggests 660.03% Upside
As of March 4, 2023,
the average one-year price target for Geovax Labs is $5.78.
The forecasts range from a low of $3.03 to a high of $8.40.
The average price target represents an increase of 660.03% from its latest reported closing price of $0.76.
The projected annual revenue for Geovax Labs
is $10MM, an increase of 4,038.13%.
The projected annual non-GAAP EPS
is -$0.50.
What are large shareholders doing?
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares
holds 440K shares
representing 1.67% ownership of the company.
No change in the last quarter.
Renaissance Technologies
holds 410K shares
representing 1.56% ownership of the company.
In it’s prior filing, the firm reported owning 1,046K shares, representing
a decrease
of 154.72%.
The firm
decreased
its portfolio allocation in GOVX by 78.03% over the last quarter.
VEXMX – Vanguard Extended Market Index Fund Investor Shares
holds 289K shares
representing 1.10% ownership of the company.
In it’s prior filing, the firm reported owning 108K shares, representing
an increase
of 62.73%.
The firm
increased
its portfolio allocation in GOVX by 49.49% over the last quarter.
Geode Capital Management
holds 173K shares
representing 0.66% ownership of the company.
In it’s prior filing, the firm reported owning 146K shares, representing
an increase
of 15.32%.
The firm
decreased
its portfolio allocation in GOVX by 37.16% over the last quarter.
FSMAX – Fidelity Extended Market Index Fund
holds 122K shares
representing 0.47% ownership of the company.
In it’s prior filing, the firm reported owning 32K shares, representing
an increase
of 74.19%.
The firm
increased
its portfolio allocation in GOVX by 159.42% over the last quarter.
What is the Fund Sentiment?
There are 25 funds or institutions reporting positions in Geovax Labs.
This is a decrease
of
4
owner(s) or 13.79% in the last quarter.
Average portfolio weight of all funds dedicated to GOVX is 0.01%,
an increase
of 3.45%.
Total shares owned by institutions decreased
in the last three months by 27.26% to 2,301K shares.
Geovax Labs Background Information
(This description is provided by the company.)
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
[ad_2]
Image and article originally from www.nasdaq.com. Read the original article here.